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Abstract 
 
 Natural Killer (NK) cells are highly cytotoxic and specific towards certain types of 
cancer cells and are therefore a potential target for immunotherapy.  In order to determine 
how NK cells acquire these traits, K562-mb15-41BBL cancer cells, specially modified 
leukemia cells designed to enhance NK cells for cancer eradication, were tagged with an 
Alexa Fluor 647 (A647) fluorescent dye and cultured with peripheral blood mononuclear 
cells (PBMCs) over a week.  Non labeled K562-mb15-41BBL cells were used as a control.  
The co-incubation of PBMCs and K562s is intended to show which cells from the mixed 
PBMC culture interact directly with the cancer cells by way of A647 dye transfer. K562s can 
specify NK cells and increase cytotoxicity, but the using of whole K562 cell is inapplicable in 
a clinical setting.  To test a new strategy, plasma membrane (PM) particles made from the 
K562-mb15-41BBL were labeled and cultured with PMBCs.  Results were obtained by flow 
cytometry, utilizing specific antibodies CD56, CD14, and CD3 to identify labeled NK cells, 
natural killer-like T cells (NKT) and T cells.   K562-mb15-41BBL cells labeled mostly (NKT) 
cells, with little expression of the A647 on pure NK cells, while PMs labeled NK cells and T 
cells at high rates, indicating that the first step of NK expansion involves direct contact with 
K562 cells.  Further studies should be aimed at distinguishing the two culturing methods, to 
determine if the size of K562 cells inhibits the specification of NK cells and how to reduce T 
cell interaction with the K562-mb15-41BBL cells to allow for higher amounts of NK 
expansion.  Determining how NK cells interact with K562-mb15-41BBL cells will allow for 
faster expansions of NK cells in the future, leading to improved and better treatments when 
this method of immunotherapy eventually moves to clinical trials. 
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Introduction 
 Cancer affects every race, height, weight, sex, and aged person in the world and killed 8.2 
million people worldwide in 2012 (Stewart 2014).  Treatment of this disease would solve one of 
the world’s most destructive sicknesses. The conventional methods for treating cancer consist of 
chemotherapy, radiation, and surgical removal.  Traditional chemotherapy targets the cancer cells 
by preventing their mitosis, or cell division, in some manner- often by disrupting replication via 
genetic mutation (Malhotra and Perry, 2003).  Radiation is used to further mutate the cancer cells 
beyond the point of reliable replication, causing their death.  Surgery removes tumors from the 
body to prevent the cancer from spreading to other parts of the body. It also reduces the number of 
cancer cells that chemotherapy and radiation would have to target.  These three treatments are 
often used in conjunction with each other in order to maximize the benefits.  The treatments are not 
without their side effects, however.  Chemotherapy is not specific to cancer cells; rather it targets 
any rapidly dividing cells, which include healthy epithelial cells in the stomach lining, bone 
marrow cells, hair follicles, and testes (Corrie, 2008; Malhotra and Perry, 2003).  Radiation cannot 
be localized to purely cancerous cells, and so healthy cells that reside around the cancer can 
actually be turned cancerous (Schneider, 2011).  Surgery can only remove large groups of 
cancerous cells.  If it were to miss a single cell, cancer could theoretically reemerge in the patient 
from cancer stem cells.  The existing forms of cancer treatment are, while advancing, clearly 
flawed at their roots.  A better method of treatment is needed, and it is currently being researched 
through the treatment of the hallmarks of cancer. 
First defined at the cellular level by Douglas Hanahan and Robert Weinberg (2000), the 
hallmarks of cancer have ten characteristics: sustaining proliferative signaling, evading growth 
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suppressors, avoiding immune destruction, enabling replicative immortality, tumor-promoting 
inflammation, activating invasion and metastasis, inducing angiogenesis, genome instability and 
mutation, resisting cell death, and deregulating cellular energetics (Hanahan and Weinberg 2011).  
Although new therapies have emerged in the past decade to explicitly target the cellular hallmarks 
of cancer, termed “the rational treatment of cancer”, some of these strategies are still in their 
infancy (Hanahan and Weinberg, 2011).   Immunotherapy, or the boosting of the body’s natural 
immune system to fight cancer, and the method under investigation here, is a potential cure with 
minimal side effects to the patient.  In this study, the goal is to understand the cellular signaling 
pathway of natural killer (NK) immune cells, with regards to the specific interaction between K562 
cancer cells and the NK cells, resulting in expansion of the NK cells as part of a possible cancer 
treatment plan. 
 
Cells of The Immune System 
 The immune system is the body’s way of protecting itself from bacteria, viruses, parasites, 
and rogue cells, such as cancer.  It is split into two primary functioning parts:  the adaptive immune 
system and the innate immune system (Parkin and Cohen, 2001).  Both seek to remove all of the 
aforementioned threats; they merely go about it in different ways.   
The adaptive immune system consists of two primary cell types:  T lymphocytes and B 
lymphocytes.  T lymphocytes are distinguished from B lymphocytes in that they present a T-cell 
receptor on their membranes, and the cells mature in the thymus.  B lymphocytes, by contrast, 
express B-cell receptors on their membranes and originate and mature in bone marrow.  The 
function of T lymphocytes is to induce cell apoptosis, but different types of T lymphocytes go 
about the process in different ways (Parkin and Cohen, 2001).  One type of T lymphocyte (CD8+ T 
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lymphocyte) recognizes an antigen that is presented by an infected cell (Guermonprez et al., 2002; 
Parkin and Cohen, 2001).  This antigen is presented to the CD8+ T lymphocyte through a MHC 
class I molecule located on the infected cell (Gao and Jakobsen, 2000; Guermonprez et al., 2002). 
The T lymphocyte has a reciprocal receptor on its membrane, the CD8 receptor, and when it 
recognizes the antigen, it causes the infected cell to initiate cell apoptosis via a molecule called 
perforin (Parkin and Cohen, 2001).   Other T lymphocytes, like CD4+ T lymphocytes, recognize 
antigens presented via MHC class II molecules on infected cells.  These infected cells are 
phagocytized by macrophages and other innate immune system cells, broken down, and their 
corresponding antigens are attached to MHC class II molecules.  CD4+ T lymphocytes do not 
directly initiate cell apoptosis, instead releasing cytokines like interleukin-2 (IL-2) and interferon-γ 
(IFN-γ) which causes CD8+ cells, B lymphocytes and macrophages, respectively, to activate and 
destroy harmful cells (Parkin and Cohen, 2001; Zhu et al., 2010). 
B lymphocytes remove antigens from the blood, but rather than acting on the infected cells 
themselves, the B lymphocytes target antigens while they reside in the bloodstream (Parkin and 
Cohen, 2001). B lymphocytes use antibodies such as IgM, IgG, and IgA to overwhelm antigens in 
the blood and do not induce apoptosis (Clark et al., 2004; Parkin and Cohen, 2001).  They instead 
bind to free-floating antigens or ones bound to MHC class II molecules in macrophages (Parkin 
and Cohen, 2001). Once the B lymphocytes have found an antigen, they proliferate into short-term 
plasmoblasts, which remove the immediate antigen problem by secreting large amounts of 
antibodies to overwhelm the pathogen, and memory B lymphocytes, which remain in the body in 
case of a secondary infection by the same pathogen (Parkin and Cohen, 2001).  This process, 
however, does not happen without the assistance of helper T lymphocytes, which stimulate the 
further production of B lymphocytes via cytokines (Clark et al., 2004; Parkin and Cohen, 2001). 
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 The body’s first line of defense against invasive agents such as pathogens, worms, and 
parasites is the innate immune system (Hato and Dagher, 2015).  The first responding cells are 
typically neutrophils, followed closely by macrophages and dendritic cells (Hato and Dagher, 
2015; Parkin and Cohen, 2001).  Upon finding a pathogen, the cells phagocytize it and release 
cytokines that activate inflammation in the surrounding tissue (Hato and Dagher, 2015).  These 
cells are responsible for recruiting adaptive immune cells such as T lymphocytes and B 
lymphocytes by producing MHC class II receptor molecules. After this initial response, other 
innate immune cells are able to respond to the infection.  These cells include additional neutrophils, 
basophils, eosinophils, phagocytes, mast cells, and NK cells (Parkin and Cohen, 2001) .  
Neutrophils, the most abundant phagocyte, kill invasive bacteria and other pathogens with the 
granules contained within them.  Similarly, basophils and eosinophils release reactive agents, 
histamine and toxic proteins, respectively, to destroy the invasive pathogens (Jiang and Zhou, 
2015).  Mast cells also release histamine, although these cells primarily reside in mucosal 
membranes and connective tissues, and are responsible for summoning neutrophils and 
macrophages to the site of infection (Parkin and Cohen, 2001).  
 
T Cell Immunotherapy 
 Modifying the immune system to create a therapy is considered a possible treatment for 
cancer.  Modifying T lymphocytes for cancer treatment is a field currently being explored by the 
immunotherapy community (Jiang and Zhou, 2015; Simon et al., 2007; Singh et al., 2011).  After 
IL-2, an interleukin that signals growth of immune system lymphocytes, was discovered in the 
supernatant of T lymphocytes in 1976 it has been used to help culture immune cells (Morgan et al., 
1976; Sim and Radvanyi, 2014). IL-2 was also used to boost the cytotoxicity of both T 
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lymphocytes and NK cells in clinical trials (Welte et al., 1982). IL-2 is essential for the 
development of T lymphocytes and activating T lymphocytes to induce cell death (Jiang and Zhou, 
2015).  It was then determined that if T lymphocytes were cytotoxic to cancerous cells, expanding 
them with IL-2 would help treat cancer.  Large amounts of IL-2 were used to treat patients with 
metastatic melanoma, causing remission in 5-10% of patients and curing up to 70% of those 
patients (Rosenberg 2012).  If too much IL-2 is injected into patients, they can experience a fatal 
side effect called capillary leak syndrome, creating a serious drawback to IL-2 immunotherapies 
(Bachanova and Miller, 2014; Miller, 2015). IL-2 therapies were not as successful as intended, 
especially with capillary leak syndrome as a potential side effect, leading to the use of T 
lymphocytes in immunotherapy (Sim and Radvanyi, 2014). 
 The use of pure T lymphocytes in cancer immunotherapy is extensive.  One such example 
is in the field of tumor infiltrating lymphocytes (TILs).  These TILs are isolated from the tumors of 
the individual themselves and are specific for the tumor’s antigens.  Over 50% of malignant 
melanoma patients received a significant response when treated with autologous TILs.  These TILs 
are now able to be expanded, or allowed to selectively proliferate, ex vivo and have lead to clinical 
trials for patients with extreme cases of malignant melanoma (Junker et al., 2012).  The IL-2 
problem remains, however, as large amounts of this cytokine are needed to keep the TILs in high 
numbers (Miller, 2015; Sim and Radvanyi, 2014).  Additionally, in order to expand the TILs 
properly, surgery must be performed to obtain pieces of the tumor, making it a less than ideal 
strategy for patients with tumors in difficult to reach places (Junker et al., 2012). 
 Another form of T lymphocyte immunotherapy is chimeric antigen receptor T lymphocyte 
based therapy (CAR-T) (Bagg and June, 2011; Singh et al., 2011).  These chimeric antigen 
receptors, which are isolated from expanded T lymphocytes, combine a specific antibody domain 
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with that of a CD3 chain (Bagg and June, 2011).  With the inclusion of CD137, also known as 4-
1BB, a signaling domain for tumor necrosis factor, CAR-Ts were able to persist in vivo, allowing 
for better cancer cytotoxicity (Bagg and June, 2011).  CAR-T cells are specifically needed because 
in cancerous cells, MHC presenting molecules are often down regulated, creating a scenario in 
which most immune system cells are unable to recognize the cancerous cells (Hanahan and 
Weinberg, 2011).  CAR-T cells, however, are able to recognize these cancerous cells with MHC 
down-regulation (Jiang and Zhou, 2015).  An issue arises, however, when choosing the target 
receptor that the CAR-T must affect on the cell.  Cancerous or not, many cells have the same 
receptors; a good example lies in malignant and healthy B lymphocytes, which both express CD19 
receptors (Bagg and June, 2011; Davila et al., 2014).  The CAR-T cells in one study removed the 
malignant cells well, but in subsequent months the patients could not regrow B lymphocytes, as the 
CAR-T cells were still targeting them, healthy or not (Bagg and June, 2011).  Thus, even 
engineered T lymphocytes fail to safely and reliably treat cancer and need additional aides such as 
surgery or IL-2 to continue proliferating in vivo, making them an unreliable treatment option in 
their current state. 
 
Natural Killer Cells in Immunotherapy 
 Due to the limited success of T lymphocyte immunotherapy, NK cells are currently being 
considered as a model for cancer treatment.  NK cells, which were originally considered part of the 
innate immune system and are now considered both innate and adaptive, do not attack invasive 
pathogens (Vivier et al., 2011).  Rather, they attack infected or abnormally growing host cells, 
inducing apoptosis in the target cell (Yoon et al., 2015). They will also attack cancerous cells, 
providing a line of defense against harmful cells produced by the host (Vivier et al., 2012).  This 
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is done through the recognition of an abnormally low number of MHC class I molecules present 
on the surface of the cell, a trait that normally is present only in cancerous cells (Shifrin et al., 
2014).  The difference between these cells and those of the adaptive immune system is that the 
NK cells do not require pre-activation.  Rather, the NK cells are able react immediately to the 
cancer, making them ideal in fighting it. 
 NK cells were originally classified as part of the innate immune system (Vivier et al., 
2011).  This, generally speaking, would relegate them to a short-lived lifespan and prevent them 
from adapting to various pathogens, as adaptation is what defines the adaptive immune system.  In 
recent years, however, it has been discovered that NK cells are capable of adapting and surviving 
long-term (Min-Oo et al., 2013).  These studies have specifically focused on virus-driven 
pathogens, but the discovery of the memory-like NK cells leads to future questions about the 
ability of NK cells to function in immunotherapy against cancer.  A study has been conducted to 
determine how NK cells preactivated with IL-12/15/18 affect tumors and cancer cells, and they 
concluded that NK cells that are activated with IL-12/15/18 respond effectively against cancer, and 
even interact with CD4+ T lymphocytes, the cells specifically used to activate and change other 
adaptive cells.  The NK cells in this study were injected into tumor-ridden mice, and when 
combined with irradiation, reduced the growth of tumor size.  Furthermore, the NKs gathered in 
tumor tissue and persisted in high numbers, but only in the presence of CD4+ cells, due to the IL-2 
produced by these cells.  This IL-2 was also essential in the rapid expansion of the NK cells, which 
was determined by the high levels of IL-2 receptor chains present on the IL-12/15/18 preactivated 
NK cells (Ni et al., 2012).   
NK cells have also been cultured with K562 cells, which are immortalized myelogenous 
leukemia cells.  The NK cells cultured with the K562 cells seem to retain a memory-like state 
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when reintroduced to K562s (Romee et al., 2012).  It stands to reason, then, that NK cells might be 
an ideal cell type for use in cancer immunotherapy. 
 In order to use NK cells as an effective treatment for cancer, the number of cancer-seeking 
NK cells present in the body must be increased.  The expansion of NK cells functions similarly to 
that of T lymphocytes, where low doses of IL-2 cause NK cell proliferation and expansion 
(Bachanova and Miller, 2014; Sim and Radvanyi, 2014; Yoon et al., 2015).  At high doses in vivo, 
however, IL-2 proves to be quite hazardous, causing capillary leaking in many patients (Bachanova 
and Miller, 2014).  Additionally, IL-2 proliferates T lymphocytes as well as NK cells.  These T 
lymphocytes take up the IL-2 at rates much higher than NK cells, preventing pure IL-2 
introduction from being a usable immunotherapy methodology (Simon et al., 2007).  Another 
immunotherapeutic method involves utilizing the body’s own NK cells and increasing their 
cytotoxicity via antibody dependent cell-mediated cytotoxicity (ADCC).  This method requires the 
administration of activating cytokines such as IL-12, IL-2, and IL-21, as well as various antibodies 
like disaloganglioside to alter the NK Fc receptor CD16 (Alderson and Sondel, 2011; Cheng et al., 
2013).  This type of activation is effective, but only for tumor cells that utilize the ADCC effector 
pathway and is therefore not useful in all patients. 
 A methodology must be created so that NK cells can be expanded outside the body without 
expanding T lymphocytes, so as to minimize IL-2 usage as well as potential damage to the 
recipient when reintroduced.  Furthermore, this methodology must be relatively rapid in order to be 
considered a proper treatment for cancer.  Therefore, an ideal NK cancer immunotherapy involves 
an artificial expansion of NK cells ex vivo and the reintroduction of said cells in vivo (Bachanova 
and Miller, 2014).  Pure transplants of ex vivo expanded, allogeneic NK cells into the patient was 
effective, with positive results against renal cell carcinoma and Hodgkin’s disease, while 
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simultaneously having few negative side effects (Cheng et al., 2013)  When transplanted, 5 of 19 
patients with poor-prognosis went into complete remission.  These remissions were accompanied 
by highly increased levels of IL-15, a chemokine, essential for NK expansion, suggesting that the 
NK cells could expand in vivo (Miller et al., 2005).  Unfortunately, the patient’s own immune 
system rejects the unfamiliar NK cells over time (Vivier et al., 2012). It is possible to expand NK 
cells in vivo that come from NK cell lines, such as NK-92 or NKL cell lines (Cheng et al., 2012).  
The benefit of these cell lines is an increased cytotoxicity to many different types of cancers, due to 
the large variety of receptors present on the NK cells.  The process itself is considered safe enough 
to have begun FDA approved testing on advanced malignant melanoma patients in the United 
States (Cheng et al., 2012).  This particular strategy, while effective, also suffers from immune 
rejection, rendering it less effective.  Therefore, auto-expansion, or the expansion of a person’s 
own NK cells, is the only currently plausible method of NK immunotherapy.  My thesis project 
sought to resolve some of the problems of generating a NK culture with an individual’s own cells. 
 
Culturing Natural Killer Cells 
 In order for NK cells to expand, they must be cultured with the proper growth factors, as 
well as a high concentration of potential targets for the NKs, in this case K562 leukemia cells 
(Cheng et al., 2012).  The goal of the culture is to expand the NK cells without letting the cancer 
cells expand out of control.  For this reason, K562 cells are treated using mitomycin c, a DNA 
cross-linking agent, which prevents the cells from proliferating (Bae and Lee, 2014).  This 
essentially makes the K562 cancer cells into a food source for the NK cells, which along with IL-2 
creates ideal conditions for expansion (Figure 1).  When cultured together along with IL-2, cell 
expansion was significantly increased.  Unfortunately, the expansion of cells includes T 
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lymphocytes, which does not solve the issue of pure NK cell expansion.  This culture, however, 
also increased cytotoxicity against many different types of cancer cell lines, like Jurkat, a T 
lymphocyte leukemia line, and MCF-7, a human breast cancer cell line (Bae and Lee, 2014).  This 
shows that the theory of expansion is correct, but the method of doing so is imperfect. 
 A method had to be developed to avoid the T lymphocyte expansion issue without 
excessive IL-2 addition.  A procedure was developed that would allow NK cells to come into 
contact with the surface receptors required for expansion, while keeping T lymphocyte levels 
within a reasonable limit.  This process involved creating a K562 cell line that expresses membrane 
bound IL-15 and 4-1BBL known also as CD137, on its surface (Oyer et al., 2015).  IL-15 is a 
cytokine that activates NK cells and specifies them for cancer destruction (Ni et al., 2012).  4-
1BBL is a trans-membrane cytokine that interacts with T lymphocytes, specifically CD8+ 
lymphocytes (Mittler et al., 2004).  These membrane-bound proteins allow for activation of the NK 
cells to seek and destroy the cancer cells.  Expansion using these engineered K562 cells, called 
K562-mb15-41BBL cells, creates a 277-fold expansion over three weeks and keeps T lymphocyte 
counts between 5% and 65% (Oyer et al., 2015).  Therefore, the added membrane-bound receptors 
do not negatively influence the NK cells proliferation or function and can be used for expansion of 
NK cells without fear of a negative impact. 
 This method remains flawed, however, for use beyond the purely experimental.  There is 
no conventional way to sort peripheral blood mononuclear cells (PBMCs), the source from which 
NK cells are proliferated, out from a culture.  Furthermore, injection of the whole culture would 
result in placing new cancer cells (K562s) into the patient’s body- a less than advisable practice.  
The cancer cells have been treated with the mitomycin c, but the chance of injecting even one 
living cancer cell is too high.  A novel method was created to culture the NK cells without the 
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threat of transmitting cancer- the creation of plasma-membrane particles from K562-mb15-41BBL 
cancer cells (Oyer et al., 2015).  The K562-mb15-41BBL cells have IL-15 and ligand 41BB bound 
to the membrane, creating focus points for the NK cells to target. Creating the K562-mb15-41BBL 
cancer cells and then lysing them in a nitrogen cavitation vessel synthesizes the particles.  The 
particles contain all the membrane bound cytokines the original cancer cells had, but now are 
destroyed, preventing them from potentially proliferating inside a patient. The plasma membrane 
particles not only help NK cells proliferate, but they also cause all other types of PMBCs to 
decrease over time (Figure 2), maximizing the effectiveness of the treatment (Oyer et al., 2015).  
The only problem with this method of NK proliferation is that the mechanism by which the PM 
particles interact with the PBMCs is currently unknown.  The current hypothesis suggests that 
there may be an intermediate reaction involving macrophages or other phagocytizing cells, perhaps 
even through CD4+ T lymphocytes.  Understanding this pathway could lead to potentially more 
expedient and efficient expansions in the future.  
 
Experimental Objective 
 This study was designed to determine which PBMC cells interact with K562-mb15-
41BBL.  This information will be used to better determine the mechanism by which the NK cells 
initiate expansion.  If this mechanism is determined, then a streamlining of the process may be 
attempted, allowing for better NK cell purification for immunotherapy. 
 Alexa Fluor® 647 is a fluorophore that attaches to any surface proteins that it contacts (Life 
Technologies, 2012).  Additionally, when more Alexa Fluor is added, the dye gets brighter, 
allowing for visualization of areas that are repeatedly contacted.  The dye is viewed in the 655 nm 
wavelength and is easily detectable in a flow cytometer.  Therefore, to determine the way in which 
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K562s interact with NK cells, we can stain K562s with Alexa Fluor® 647 (A647) and image 
following days of expansion in a mixed culture.  Each cell that contacts a labeled K562 cancer cell 
will pick up the dye.  Using a Canto Flow Cytometer, it is possible to individually count and sort 
every PBMC cell in the culture.  A flow cytometer takes a sample of cells and counts them 
individually by firing a laser at each cell.  The cells are stained with antibodies that are specific for 
a certain channel, or wavelength, and therefore can be seen as distinct from the other cells.   
By adding antibodies that detect specific cell types, it is also possible to sort out and individually 
identify each newly labeled PBMC cell.  Therefore, it is possible to determine which cells came 
into contact with the A647-K562-mb15-41BBL cells by tracing the A647 wavelength.  This would 
show where A647 dye had been transferred from the A647-K562 cells, indicating an interaction.  
Pure NK cells are CD56 +, CD3 -; NKT cells, NK cells that display T lymphocyte-like 
characteristics, are CD56 +, CD3 +; and T lymphocytes are CD56 -, CD3 + (Table 1).  It is 
possible then, when sorting for the antibodies that correspond with these markers, to determine if 
the A647 has interacted with these particular cell types.  This will give us insight as to how the NK 
cells and K562-mb15-41BBL cells interact.  In turn, this information will allow for better future 
NK cell expansion, and eventually better treatment of future cancer patients. 
 
Table 1. The receptors of PBMC cells important to this study. 
 CD56 - CD56 + 
CD3 - Other PBMCs NK Cells 
CD3 + T cells NK-like T Cells 
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Methods and Materials 
Cell Culture and PM particle production 
 Cultured K562-mb15-41BBL cells were harvested and centrifuged at 1000xg for 10 
minutes at 4˚C.  Supernatant was aspirated, and the cells washed with 100 mL DPBS containing 
2mM EDTA.  The cells were then centrifuged at 1000xg for 10 minutes at 4˚C.  Supernatant was 
aspirated, and the pellet collected, weighed, and suspended in homogenization buffer (150mM 
NaCl, 2mM MgCl2, 20mM HEPES, pH 7.4) and protease inhibitor (10µg/mL Leupeptin, 
10µg/mL Aprotinin, 10µM Pepstatin A, 1 mM AEBSF), where the buffer and inhibitor were 
added at 10x the weight of the pellet, in mL.  The contents were then transferred to the nitrogen 
cavitation vessel and pressurized at 300 psi for 30 minutes at 4˚C.  Homogenate was then 
collected and centrifuged at 1000xg for 10 minutes at 4˚C.  The supernatant was aspirated, and 
then the pellet resuspended in homogenization buffer.  The homogenate was then centrifuged at 
100,000xg for 2 hours at 4˚C.  The supernatant was aspirated, and the pellet was resuspended in 
6mL of homogenization buffer in a bath sonicator at 27˚C for 25 minutes.  Sixteen milliliters of 
75% sucrose containing 25mM HEPES was also added while the mixture is in the sonicator.  
The mixture was then transferred to tubes, and sucrose containing 25mM HEPES was added to 
be 25% of the solution.  The mixture was then placed in the SW41Ti rotor and centrifuged at 
40,000xg for 17 hours.  After centrifugation, the top 1-3 mL of supernatant was discarded.  The 
volume was then brought up with 1X DPBS and placed in a 70.1 rotor and centrifuged at 
100,000xg for 2 hours.  After, the supernatant was removed, and the pellet resuspended in 1X 
DPBS, with the following equation- (Total pellet weight)/0.33= x mL DPBS.  The product was 
then frozen in -80˚C. 
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K562-mb15-41BBL cells, for use in cellular cultures, were treated to prevent replication.  
K562-mb15-41BBL cells were obtained from an already existing culture at about 1.5 million 
cells/mL.  Cells were centrifuged at 200xg for 5 minutes at room temperature, supernatant 
removed and resuspended at a concentration of 1.0x107 cells/mL in RPMI. Mitomycin C was 
added at 50 µL/mL of culture, mixed, and left to incubate for 30 minutes, mixing every 10 
minutes to prevent cells from sticking to the walls of the centrifuge tube and to allow even 
treatment for each cell.  To rinse, RPMI was added to bring the culture to about 1.0 x106 
cells/mL and centrifuged at 200xg for 5 minutes.  The rinsing process was repeated twice with 
RPMI, and then twice with Dulbecco’s phosphate-buffered saline (DPBS) at a pH of 7.6. 
Alexa Fluor 647 Labeling 
K562-mb15-41BBL cells and plasma membrane particles were labeled with Alexa Fluor 
647 (A647).  The following process is the same for both cells and plasma membrane particles.  
The treated K562-mb15-41BBL cells or particles were split into two samples, one to be 
fluorescently labeled and the other to serve as a negative control.  They were centrifuged at 
200xg for six minutes. The cells or particles were suspended to 1.0 x106 cells/mL (4.32 mg/mL 
for plasma membranes) in PBS pH 7.6, and the A647 was added at a final concentration of 
8.0x10-7 M. The cells or particles were left to incubate for one hour, resuspending every 10 
minutes for better labeling.  The cells were spun and washed at 200xg for 5 minutes with RPMI 
containing 5% Fetal Bovine Serum (FBS) media, which functions as simulation blood, and 
resuspended at 3.33x106 cells/mL in RPMI containing 5% FBS media.  The cells or particles 
were run on a BD Accuri C6 Flow Cytometer (BD Biosciences, San Jose, CA) using a cocktail 
containing 1µL/sample CD56-PE (a fluorescent dye to label cells that have CD56 receptors, BD 
Bioscience Cat# 130-090-755), 1µL/sample CD3-APC (a fluorescent dye to label cells that have 
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CD3 receptors, Beckman Coulter, Cat# IM2467), and 9µL/sample DPBS containing 2mM 
EDTA and 0.5% BSA, to determine if the cells were properly labeled. 
The labeled and unlabeled K562-mb15-41BBL cells were cultured with PBMC cells to 
create an environment where NK cells could expand.  A leukopack, which is a concentrated 
sample of PBMCs, was thawed at 37˚C for exactly 3 minutes, and 1mL of the leukopack was 
added to 10mL RPMI containing 5% FBS, mixed, and centrifuged at 200xg for 8 minutes.  The 
supernatant was removed, and the cells were resuspended in 1mL of stem cell growth media 
(SCGM) containing 10% FBS and IL-2 (100U/mL).  A sample was taken and mixed with the 
aforementioned Accuri cocktail in a 1:1 mixture and left to sit for 10 minutes in the dark.  1X 
DPBS was added at 4:1 to the mixture, and 50 µL ran on a BD Accuri C6 Flow Cytometer (BD 
Biosciences, San Jose, CA).  Using the equations below, the amount of PBMCs, K562-mb21-
41BBLs, and SCGM containing 10% FBS and IL-2 to be added to the plates was determined. 
 
𝑆𝐶𝐺𝑀 𝑀𝑒𝑑𝑖𝑎 𝑈𝑠𝑒𝑑 (𝑚𝐿) = (#𝑤𝑒𝑙𝑙𝑠)  ×  (𝑉𝑜𝑙𝑢𝑚𝑒 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 (200 µ𝐿)) 
 
(𝐼𝐿 − 2) 𝑎𝑑𝑑𝑒𝑑 (µ𝐿) = (𝑆𝐶𝐺𝑀 𝑎𝑚𝑜𝑢𝑛𝑡)/(10,000) 
 
# 𝑜𝑓 𝑉𝑖𝑎𝑏𝑙𝑒 𝑁𝐾 𝑐𝑒𝑙𝑙𝑠 = (
(𝑃2 𝑒𝑣𝑒𝑛𝑡𝑠) × (200)
1,000
) × (%𝑁𝐾 𝑖𝑛 𝑃𝐵𝑀𝐶) × (%𝑁𝐾 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦) 
 
The P2 events, which are events that fall within a certain gated range of cells, were calculated on 
the Accuri C6 Flow Cytometer.  Some NK cells are not considered viable for expansion, due to 
their preexisting nature.  This is why the number of viable NK cells was calculated.  The NK 
cells were seeded at 1:10 against feeder cells.  The K562-mb15-41BBLs, PBMCs, and media 
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were all pre-mixed together, the control and labeled cells separate, and then plated in a 96-well 
plate in 100 µL aliquots.  K562-mb15-41BBL cells by themselves were plated, as well as raw, 
untreated PBMCs as controls.  The plate was left to grow in the 37˚C incubator for 5 days. 
The cultured cells were run through a flow cytometer to determine which cells were 
expanding.  Six tubes were obtained for samples, two were filled with labeled and unlabeled 
cultures (PBMC + K562-mb15-41BBL), respectively, 90 µL each from the 96-well plate.  The 
remaining four vials were filled with pure K562-mb15-41BBL cells, 90 µL each.  Versene, an 
EDTA cell dissolution agent, was then added to the wells that had previously held the K562-
mb15-41BBL and PBMC cultures, at 50 µL/well, and stored in the 37˚C incubator for 10 
minutes.  After 10 minutes, the Versene was removed from the 96-well plate and added 
respectively to the vials containing the sample that corresponds with the well.  Two hundred 
microliters of 1X DPBS was added to each of the tubes.  The samples were spun at 200xg for 5 
minutes, and the supernatant was aspirated.  A flow cytometry cocktail was created according to 
table 2. 
 
Table 2: Flow Cytometry cocktail for determining the cells present in the PBMC + K562-
mb21-41BBL culture. 
Flow Cytometer Cocktail Amount 
CD3-Alexa 488 (eBioscience, Cat# 53-0037-42) 2.5 µL x 1.1 x #samples 
CD14 PE (BD Bioscience, Cat# 555398) 2.5 µL x 1.1 x #samples 
CD19-PC7 (BD Bioscience, Cat# 349209) 2.5 µL x 1.1 x #samples 
CD56-BV421 (BD Bioscience, Cat# 562751) 1.5 µL x 1.1 x #samples 
Flow Buffer (DPBS containing 2mM EDTA and 50 µL x 1.1 x #samples 
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0.5%BSA) 
 
 
Fifty microliters of the cocktail were added to each tube except for two samples, one containing 
K562-mb15-41BBL labeled cells and K562-mb15-41BBL unlabeled cells, to which 50 µL of 1X 
DPBS was added.  The samples were let to sit in a 4˚C refrigerator for 30 minutes.  After, 200 
µL of 1X DPBS was added to each, and the samples ran on a BD FACSCANTO II flow 
cytometer (BD Biosciences, San Jose CA). 
 
Results 
K562-mb15-41BBL cells and plasma membrane particles were successfully stained 
 In order to determine if K562-mb15-41BBL cells and plasma membrane particles were 
stained so that they could be used for NK expansion, flow cytometry was conducted. Alexa 647 
labeling was a success, with the labeled cells showing a bright signal at 104-105, which shows the 
strength of the A647 signal, and the unlabeled cells showing a signal at 0-103 levels (Figure 3).  
There is some overlap between the labeled and unlabeled cells at 103, but at significantly lower 
levels than the labeled. Expression of Alexa Fluor 647 is seen exclusively in stained plasma 
membrane particles, exhibiting bandwidths of 104-106, while the unstained K562-mb15-41BBL 
particles have a lower emission from 0-103. 
 
K562-mb15-41BBL cells were successfully cultured with PMBCs 
 In order to determine if K562-mb15-41BBL cells interacted with NK cells, PMBC cells 
were cultured with K562-mb15-41BBL cells and measured using flow cytometry.  The stained 
K562 mb-15 cells, when cultured with PBMCs, exhibit growth patterns, expanding beyond the 
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initial high concentration of T cells (Figure 4).  Initial A647 levels were about 16% on the first 
day of flow cytometry in NK cells, and dropped drastically to less than 1% on day 2, with a very 
slow increase trending towards 1% on subsequent days (Figure 5).  In NKT cells, the labeled cell 
percentage is near 100% and drops to about 40%, but rises in conjunction with the unlabeled 
percentage (Figure 5).  Furthermore, in other cells present in the sample, such as macrophages, 
there was a sharp decrease in labeled cells’ A647 percentage from 6.8% on day one to 0% in 
subsequent days, while in labeled NK cells A647 percentage rose from a little over 0% to 3.75% 
(Figures 6A, 6B).  Unlabeled NK cells also rose from 0.8% to 3.98% A647, showing that this 
may just be background noise, as the unlabeled cell cultures that should show no A647 dye are 
showing similar amounts to the labeled cell cultures (Figure 4). iNK cells went from 1.9% A647 
on day 1 to 5.7% A647 on day 4.  Unlabeled iNK cells started at 1% A647 on day one, 
progressing up to 4.4% A647 by day 4. 
 
K562-mb15-41BBL particle membranes were successfully cultured with PBMCs 
 In order to determine how K562-mb15-41BBL PM particles stained a PMBC culture, the 
cultures were measured using flow cytometry.  Contrary to how the K562-mb15-41BBL cells 
impacted the PMBCs, the plasma membrane particles selectively expanded NK cells and T cells 
without expanding either NKT or iNK cells, as only NK and T cells showed labeling, with NKT 
and iNK showing no labeling  (Figure 7).  NK cells started off with rapid expansion from days 1-
2, rising to 60% labeled.  By day 7, NK cells had reached their most labeled at 90%, before 
declining to 60% on day 9.  T cells also were labeled by the K562-mb15-41BBL cells, but at a 
lesser rate than NK cells, only overtaking them by day 9, at 75%.   
Discussion 
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 Cancer is a disease through which the most common methods of treatment involve 
poisoning, irradiating, or cutting the body, and all suffer from significant side effects (Corrie, 
2008; Malhotra and Perry, 2003).  An upcoming form of treatment, immunotherapy, has seen 
progress in recent decades, but is not quite ready to be applied in the clinical setting. Attempts 
have been made to utilize T-lymphocytes and various cytokines in hopes of causing an expanded 
and more targeted immune system, but there have been few successful results (Denman et al., 
2012; Guermonprez et al., 2002; Singh et al., 2011; Vivier et al., 2012).  NK cells, by 
comparison, are able to remove cancer cells effectively and safely (Bachanova and Miller, 2014; 
Miller, 2013).  Activation of these NK cells by cancer cells with membrane-bound cytokines 
eliminates the toxicity encountered by injecting pure IL-2 cytokines and allows for an initial 
expansion and specificity to cancer cells before injection into the patient, creating NK cells that 
will seek only cancer cells, avoiding other immune system problems (Childs and Berg, 2013; Ni 
et al., 2012; Sim and Radvanyi, 2014).  These cultures of K562-mb15-41BBL cells and PBMCs, 
by which the NK cells are expanded, cannot be directly injected into a patient, however, as this 
can potentially give them the K562-mb15-41BBL strain of cancer, even if the K562-mb15-
41BBLs are rendered helpless.  Therefore, plasma membrane particles of the K562-mb15-
41BBLs are used to culture the NKs, as part of the cell membrane cannot transmit the cancer.  
The results of this study help to identify the specific pathways by which the K562-mb15-41BBLs 
interact with all the cells in a PBMC sample.  By learning this pathway, the proliferation of the 
NKs can potentially be increased, and the process streamlined. 
 By knowing which receptors are present on each type of immune cell, it is possible to 
sort the cells individually through a flow cytometer and determine which of the cells 
accumulated the Alexa Fluor 647 conjugate dye from the labeled K562-mb15-41BBL cells or 
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particles.  The dye transfers from the labeled cells to unlabeled cells only when the proteins 
present on the surfaces of each cell interact with each other (Technologies, 2007). Cells that are 
CD14+, regardless of other receptors, did not pick up any of the A647 dye (Figure 6).  CD14 is 
used as marker for monocytes and macrophages, as it is present on these cells to identify Gram-
negative bacteria (Jersmann, 2005).  Therefore, the labeled K562-mb15-41BBL cells do not 
interact with macrophages or monocytes, an anticipated result considering the receptors that have 
been grafted onto the K562-mb15-41BBL cancer cells (Oyer et al., 2015).  The K562-mb15-
41BBLs have membrane-bound IL-15, a cytokine that has been shown to proliferate and mature 
NK cells (Parrish-Novak et al., 2000).  This cytokine attracts the NK cells, giving the K562-
mb15-41BBLs a lower affinity for the macrophages, which are attracted to cancerous cells 
(Belgiovine et al., 2016; Hanahan and Weinberg, 2011).  As the interaction between the labeled 
K562-mb15-41BBL cells and the cells presenting CD14 is extremely low, it can be determined 
that macrophages are not part of the specification and maturation of NK cells. 
 CD56-, CD3- cells may be a form of NK cell called immature NK cells, known also as 
iNK cells (Yoon et al., 2015).  Although macrophages are not part of the specification and 
maturation of NK cells, CD56-, CD3- iNK cells might be required for the process.  The A647 
dye was transferred at about a three-fold increase to these cells (Figure 6).  It is important to note 
that the background noise in the unlabeled cells also increased the labeled samples, indicating a 
possible non-result.  The transfer of dye to iNK cells is an unusual interaction, as cells without 
CD56 or CD3 are typically not identified with either NK cells or T cells (Miller, 2015; Miller et 
al., 2005). These iNK cells cannot make up the entirety of the CD56-, CD3- population, as many 
cells exist in a PBMC sample that do not have the receptors CD56 or CD3.  If some of these iNK 
cells are affected by the labeled K562-mb15-41BBL cells, however, then they might play a role 
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in the specification of the CD56+ NK cells.  It is possible that these cells experience maturation 
and specification while in culture with the K562-mb15-41BBL cells, but as the flow cytometry 
was only carried out for a four-day period, this is still currently unknown. 
 Another subset of NK cells are prominent within PBMC samples, CD56+, CD3+ NKT 
cells.  NKT cells activate in response to cancer cells via recognition of a CD1d receptor on the 
cell.  NKTs also specify NK cells themselves to the cancer in a method similar to that employed 
by helper and cytotoxic T cells (Vivier et al., 2012).  These CD56+, CD3+ NKT cells showed 
significant accumulation of the A647 dye, more than any other cell type in the PBMCs (Figure 
5).  The background of the NKT and the unlabeled K562-mb15-41BBLs cultured with PBMCs 
also increased slightly, showing that the actual uptake of A647 might be smaller than implicated.  
As these NKT cells appear to be picking up the most A647 by a significant margin, this could be 
the first step in the proliferation and maturation of regular NK cells.  IL-15, in addition to being 
specific for NK cells, is specific for NKT cells, allowing for the NKT cells in suspension with 
the K562-mb15-41BBLs to bind.  NKT cells express 4-1BBL on their cell surface as well, which 
is necessary for the NK cells to track and destroy cancer cells, as the NKs bind to the 4-1BBL 
receptor to specify for cancer destruction (Alderson and Sondel, 2011; Cole et al., 2014).  The 
K562-mb15-41BBLs already possess 4-1BBL on their surface so to see significant amounts of 
NKT cells interacting with them may suggest that there is another mechanism at play directing 
NK and NKT cells.  If there were no other such mechanism, one would expect at least equal 
numbers of NK and NKT absorbing the A647 during initial days.  It is also possible that the IL-2 
put into the solution caused the proliferation of NKTs alongside NKs during the initial days. 
 Pure NK cells, CD56+, CD3- received little A647 in comparison with NKTs (Figure 
4A,B).  This was perhaps the most surprising result of the study, as the K562-mb15-41BBL cells 
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significantly expand pure NKs, considering the IL-15 and 4-1BBL membrane-bound cytokines 
were put there specifically to target these cells (Denman et al., 2012; Oyer et al., 2015; Parrish-
Novak et al., 2000).  The IL-2 placed into the system is known to expand T cells as well as 
NKTs, but at the quantities added, it should have expanded the regular NK cells as well.  The 
rising of the background in CD14-, CD56+, CD3- cells suggests that there was very little, if any, 
labeling transferred.  In previous trials, it is noted that regular expansion of the NK cells is not 
consistent until after the fourth day of expansion, the final day of which the cells were imaged 
(Oyer et al., 2015).  Even with this being the case, at least partial expansion of NK cells was 
expected.  Either the proposed mechanism of direct contact between K562-mb15-41BBLs and 
NKs is correct and the contact does not happen until after four days, or another method occurs 
between the two cells that does not require contact.  The activation of NK cells by NKT cells 
might be viable, as the NKT cells would make contact with the K562-mb15-41BBL cells and 
then contact the NK cells via another receptor, therefore not spreading the conjugation dye 
(Figure 8). 
 An interesting point of contradiction resides in the data received from the plasma 
membrane (PM) particles.  The PM particles labeled NK cells and T cells with startling 
efficiency (Figure 7). This discrepancy as contrasted to the labeling transferred from whole cells 
might be a result of the concentration and availability of PM particles.  As the PM particles are 
made of extruded K562-mb15-41BBL cells, they are significantly smaller than the K562-mb15-
41BBLs, allowing them to more effectively penetrate the collection of PMBC cells.  This would 
allow them to reach more NK cells, which are initially present at lower numbers than other 
PMBC cells (Oyer et al., 2015).  As the PM particles were able to reach the NK cells more 
efficiently, their membrane-bound IL-15 and 4-1BBL receptors could interact with the NK cells 
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as intended, as opposed to through the NKT cells.  T cells also picked up the A647 dye due to 
their own interactions with CD3 (Parrish-Novak et al., 2000).  More research must be done to 
determine why T cells would accumulate more A647 dye later in the expansion process.  
Additionally, more research must be conducted to determine why A647 labeled PM particles are 
superior at labeling NK cells in comparison with K562-mb15-41BBL whole cells. 
 This experiment sought to determine which PBMC cells are affected by K562-mb15-
41BBL cells using A647 dye, in an effort to better refine the NK cell maturation process.  High 
interaction between K562-mb15-41BBL and NKT cells were reported, as well as significant 
interaction between K562-mb15-41BBL and iNK cells, but not with pure NK cells.  A different 
method of NK specification may be the cause of such low NK cell labeling.  Future testing 
methods are currently being considered for how NK cells could specify to the K562-mb15-
41BBLs.  For example, the role of microRNAs in specifying ligands present on NK cells and 
cytotoxic T cells is considered an alternative route of NK cancer specificity (Jasinski-Bergner et 
al., 2014; Presnell et al., 2015).  If these microRNAs are playing a role in the specification of NK 
when introduced to K562-mb15-41BBLs, it could account for the lack of direct physical contact 
between NK and K562-mb15-41BBL. Another possible method of NK specification comes 
through exosomes, which are produced by both dendritic cells and the cancer cells (Gehrmann et 
al., 2014; Reiners et al., 2014).  These exosomes may be triggering the NKs to expand, and as 
they come from within the cell, may lack the A647 dye.  Understanding this interaction will 
allow for a better future immunotherapy, and eventually lead to successful treatment of cancers 
in a way that does not harm the body as much as surgery, radiation, or chemotherapy. 
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Appendix B:  Glossary 
 
ADCC (antibody dependent cell-mediated cytotoxicity): Administration of activating cytokines 
such as IL-12, IL-2, and IL-21, as well as various antibodies like disaloganglioside to alter the NK 
Fc receptor CD16, preventing cancer cells from proliferation. 
Alexa Fluor 647: A fluorophore that attaches to the surface proteins of cells.  Transfers when cells 
conjugate with each other. 
Auto-Expansion: The expansion of one’s own NK cells. 
B lymphocyte: white blood cell that expresses B-cell receptors on their membranes and originate 
and mature in bone marrow.  Uses antibodies such as IgM, IgG, and IgA to overwhelm antigens.  
Proliferate into short-term plasmoblasts, which remove the immediate antigen problem by 
secreting large amounts of antibodies to overwhelm the pathogen, and memory B lymphocytes, 
which remain in the body in case of a secondary infection by the same pathogen. 
CAR-T: Chimeric antigen receptor T lymphocyte based therapy.  Able to recognize cancerous 
cells with MHC down-regulation. 
CD3: Receptor present on all T lymphocytes 
CD4: Receptor on T lymphocytes that release IL-2 to cause the death of infected cells 
CD8: Receptor on T lymphocytes that directly cause apoptosis 
CD16: Receptor that is altered in ADCC-mediated therapies 
CD56: Receptor on NK cells 
CD137/4-1BBL: Signaling domain for tumor necrosis factor. Important for CAR-T and NK 
expansion. trans-membrane cytokine that interacts with T lymphocytes, specifically CD8+ 
lymphocytes 
Helper T Cell: Stimulates the production of B lymphocytes via cytokines. 
IFN- γ: Cytokine that stimulates the activation of B lymphocytes, T lymphocytes, and other 
macrophages. 
IL-2: Cytokine that stimulates the activation of B lymphocytes, T lymphocytes, and other 
macrophages, specifically NK cells. 
IL-12/15/18: Interleukins found to specify NK cells for cancer destruction.  IL-15 is of particular 
note to this study, forming the mb-15 bound part of K562-mb15-41BBL cells. 
IL-15: A chemokine essential for the expansion of NK cells.  
iNK cells:  Immature NK cells, found in PBMC samples.  Perhaps useful for specification of NK 
cells. 
K562: Immortalized myelogenous leukemia cells, specifically used for NK expansion.  
K562-mb15-41BBL: Immortalized myelogenous leukemia cells, modified to include membranous 
IL-15 and CD137/4-1BBL.  Used for NK cell expansion. 
MHC (major histocompatibility complex) Class I: Utilized on the surface of the body’s own 
cells, MHC Class I molecules present antigens from invasive pathogens for the adaptive immune 
system to recognize and act on. 
MHC (major histocompatibility complex) Class II: Found on dendritic cells, and other PBMC 
cells.  Used to activate other adaptive immune cells. 
Mitomycin C:  DNA cross-linker, used to render K562 cells incapable of mitosis. 
NK (natural killer) Cells: Considered part of both the innate and adaptive immune system, do not 
attack invasive pathogens. They attack infected or abnormally growing host cells, inducing 
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apoptosis in the target cell, including cancer cells.  They identify these cells by recognizing low 
concentrations of MHC class I molecules, a trait of cancerous cells. 
PMBC: Peripheral mononuclear blood cell.  Contains all white blood cells, purified from raw 
blood from donors. 
T lymphocyte: white blood cell that originates in the thymus and is part of the adaptive immune 
system.  There are two main types, cytotoxic T cells and helper T cells.  Cytotoxic T cells are 
CD8+ and recognize MHC class I antigen presentation, while helper T cells (CD4+) utilize IL-2 
and other cytokines to destroy MHC class II presenting cells. 
TIL (Tumor infiltrating lymphocytes):  Found in cancer cells, used for some T cell 
immunotherapies. 
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